Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ethambutol hydrochloride, quantity: 400 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; povidone; titanium dioxide; hypromellose; magnesium stearate; ethylcellulose; polyethylene glycol monomethyl ether; purified talc; maize starch; propylene glycol - ethambutol gh is indicated for the treatment of pulmonary tuberculosis, as shown by a large number of studies by investigators throughout the world. it has also been used successfully in cases of primary tuberculosis and extrapulmonary forms of tuberculosis, including miliary tuberculosis, tuberculous meningitis, tuberculosis of bones and joints, genitourinary tuberculosis, tuberculosis of the skin and tuberculous eye diseases. it should not be used as the sole antituberculosis drug, but should be used in conjunction with at least one other antituberculosis drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies.,in patients who have not received previous antituberculosis therapy, i.e. initial treatment, the most frequently used regimens have included three of the following drugs ? ethambutol, isoniazid, rifampicin and streptomycin - for the first 2-4 months. for example:,? ethambutol plus isoniazid plus rifampicin; or ? ethambutol plus isoniazid plus streptomycin,then continuing with a two drug regimen such as,? ethambutol plus isoniazid; or ? ethambutol plus rifampicin.,in patients who have received previous antituberculosis therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment cases ethambutol gh should be combined with at least one of the second-line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculosis drugs used with ethambutol have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs. isoniazid, aminosalicylic acid, and streptomycin have also been used in multiple drug regimens. alternating drug regimens have also been utilised..

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ethambutol hydrochloride, quantity: 400 mg - tablet, film coated - excipient ingredients: magnesium stearate; polyethylene glycol monomethyl ether; maize starch; povidone; hypromellose; titanium dioxide; ethylcellulose; purified talc; propylene glycol; colloidal anhydrous silica - ethambutol lapl is indicated for the treatment of pulmonary tuberculosis, as shown by a large number of studies by investigators throughout the world. it has also been used successfully in cases of primary tuberculosis and extrapulmonary forms of tuberculosis, including miliary tuberculosis, tuberculous meningitis, tuberculosis of bones and joints, genitourinary tuberculosis, tuberculosis of the skin and tuberculous eye diseases. it should not be used as the sole antituberculosis drug, but should be used in conjunction with at least one other antituberculosis drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies.,in patients who have not received previous antituberculosis therapy, i.e. initial treatment, the most frequently used regimens have included three of the following drugs ? ethambutol, isoniazid, rifampicin and streptomycin - for the first 2-4 months. for example:,? ethambutol plus isoniazid pl

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ethambutol hydrochloride, quantity: 400 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; maize starch; purified talc; magnesium stearate; ethylcellulose; hypromellose; povidone; propylene glycol; polyethylene glycol monomethyl ether; titanium dioxide - ethambutol lapl is indicated for the treatment of pulmonary tuberculosis, as shown by a large number of studies by investigators throughout the world. it has also been used successfully in cases of primary tuberculosis and extrapulmonary forms of tuberculosis, including miliary tuberculosis, tuberculous meningitis, tuberculosis of bones and joints, genitourinary tuberculosis, tuberculosis of the skin and tuberculous eye diseases. it should not be used as the sole antituberculosis drug, but should be used in conjunction with at least one other antituberculosis drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies.,in patients who have not received previous antituberculosis therapy, i.e. initial treatment, the most frequently used regimens have included three of the following drugs ? ethambutol, isoniazid, rifampicin and streptomycin - for the first 2-4 months. for example:,? ethambutol plus isoniazid pl

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ethambutol hydrochloride, quantity: 400 mg - tablet, film coated - excipient ingredients: purified talc; magnesium stearate; hypromellose; titanium dioxide; colloidal anhydrous silica; propylene glycol; ethylcellulose; polyethylene glycol monomethyl ether; maize starch; povidone - ethambutol gh is indicated for the treatment of pulmonary tuberculosis, as shown by a large number of studies by investigators throughout the world. it has also been used successfully in cases of primary tuberculosis and extrapulmonary forms of tuberculosis, including miliary tuberculosis, tuberculous meningitis, tuberculosis of bones and joints, genitourinary tuberculosis, tuberculosis of the skin and tuberculous eye diseases. it should not be used as the sole antituberculosis drug, but should be used in conjunction with at least one other antituberculosis drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies.,in patients who have not received previous antituberculosis therapy, i.e. initial treatment, the most frequently used regimens have included three of the following drugs ? ethambutol, isoniazid, rifampicin and streptomycin - for the first 2-4 months. for example:,? ethambutol plus isoniazid plus rifampicin; or ? ethambutol plus isoniazid plus streptomycin,then continuing with a two drug regimen such as,? ethambutol plus isoniazid; or ? ethambutol plus rifampicin.,in patients who have received previous antituberculosis therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment cases ethambutol gh should be combined with at least one of the second-line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculosis drugs used with ethambutol have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs. isoniazid, aminosalicylic acid, and streptomycin have also been used in multiple drug regimens. alternating drug regimens have also been utilised.

Namibia - English - Namibia Medicines Regulatory Council

strides arcolab limited - rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride - tablets - each film-coated tablet contains; rifampicin 150 mg, isoniazid 75 mg, pyrazinamide 400 mg and ethambutol hydrochloride 275 mg.

Namibia - English - Namibia Medicines Regulatory Council

svizera europe bv - rifampicin; isoniazid; pyrazinamide; ethambutol - tablet - each tablet contains rifampicin 150 mg, isoniazid 75 mg, pyrazinamide 400 mg and ethambutol 275 mg

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - isoniazid; pyrazinamide; rifampicin - tablet - 50 /300 /120 milligram(s) - combinations of drugs for treatment of tuberculosis; rifampicin, pyrazinamide and isoniazid

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - rifampicin; isoniazid - film-coated tablet - 150 mg/100 milligram(s) - combinations of drugs for treatment of tuberculosis; rifampicin and isoniazid

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - rifampicin; isoniazid - film-coated tablet - 300mg/150 milligram(s) - combinations of drugs for treatment of tuberculosis; rifampicin and isoniazid

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pahang pharmacy sdn. bhd. - rifampin usp; ethambutol hydrochloride; pyrazinamide usp; isoniazid usp -